Download PDF
Horm Metab Res 2012; 44(04): 286-290
DOI: 10.1055/s-0032-1304321
Animals
© Georg Thieme Verlag KG Stuttgart · New York

Acute Treatment with Candesartan Cilexetil, an Angiotensin II Type 1 Receptor Blocker, Improves Insulin Sensitivity in High-Fructose-Diet-fed Rats

P. Li
1   Department of Sports Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan
2   Division of Biochemistry, Aichi Cancer Center Research Institute, Nagoya, Japan
,
T. Koike
1   Department of Sports Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan
3   Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan
,
H. Y. Jiang
1   Department of Sports Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan
,
Z. H. Wang
1   Department of Sports Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan
,
Y. Kawata
1   Department of Sports Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan
,
Y. Oshida
1   Department of Sports Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan
3   Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan
› Author Affiliations
Further Information

Publication History

received 08 September 2011

accepted 19 January 2012

Publication Date:
16 February 2012 (online)

Also available at
    Permissions and Reprints

Abstract

We aimed to determine whether acute treatment with candesartan cilexetil (CV-11974), an angiotensin II type 1 receptor blocker (ARB) can improve insulin sensitivity in high-fructose-diet (HFD)-fed rats. In vivo glucose utilization was measured by applying the euglycemic clamp technique and the expression levels of insulin-signaling molecules in skeletal muscles were examined by western blotting. A bolus injection of CV-11974 improved the glucose infusion rate (GIR) of HFD-fed rats to the level of the control rats. Furthermore, restoration of impaired tyrosine phosphorylation of insulin receptor (IR) β, Akt phosphorylation at Ser473 and Thr308, and phosphorylation of the 160-kDa Akt substrate (AS160) in the skeletal muscles of HFD-fed rats were achieved by this treatment. These results suggest that acute administration of candesartan cilexetil can increase insulin sensitivity of HFD-fed rats, which is associated with improved insulin signaling in skeletal muscles.

Key words

insulin sensitivity - angiotensin II type 1 receptor blocker - high-fructose diet - euglycemic clamp - insulin signaling
 

  • References

  • 1 O’Doherty R, Stein D, Foley J. Insulin resistance. Diabetologia 1997; 40 (Suppl. 03) B10-B15
    CrossrefPubMedGoogle Scholar
  • 2 Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45: 828-833
    CrossrefPubMedGoogle Scholar
  • 3 Karlsson HK, Zierath JR. Insulin signaling and glucose transport in insulin resistant human skeletal muscle. Cell Biochem Biophys 2007; 48: 103-113
    CrossrefPubMedGoogle Scholar
  • 4 Clark MG, Wallis MG, Barrett EJ, Vincent MA, Richards SM, Clerk LH, Rattigan S. Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol Endocrinol Metab 2003; 284: E241-E258
    PubMedGoogle Scholar
  • 5 Taube A, Eckardt K, Eckel J. Role of lipid-derived mediators in skeletal muscle insulin resistance. Am J Physiol Endocrinol Metab 2009; 297: E1004-E1012
    CrossrefPubMedGoogle Scholar
  • 6 Richey JM, Ader M, Moore D, Bergman RN. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol 1999; 277 (5 Pt 1) E920-E926
    PubMedGoogle Scholar
  • 7 Engeli S, Sharma AM. Role of adipose tissue for cardiovascular-renal regulation in health and disease. Horm Metab Res 2000; 32: 485-499
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Rao RH. Effects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats. Am J Hypertens 1994; 7 (7 Pt 1) 655-660
    PubMedGoogle Scholar
  • 9 Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med 2008; 121: 656-663
    CrossrefPubMedGoogle Scholar
  • 10 Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28: 2261-2266
    CrossrefPubMedGoogle Scholar
  • 11 Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K. The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000; 18: 1605-1610
    CrossrefPubMedGoogle Scholar
  • 12 Okada K, Hirano T, Ran J, Adachi M. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res 2004; 27: 293-299
    CrossrefPubMedGoogle Scholar
  • 13 Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43: 1003-1010
    CrossrefPubMedGoogle Scholar
  • 14 Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38: 884-890
    CrossrefPubMedGoogle Scholar
  • 15 Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057
    CrossrefPubMedGoogle Scholar
  • 16 Oshida Y, Tachi Y, Morishita Y, Kitakoshi K, Fuku N, Han YQ, Ohsawa I, Sato Y. Nitric oxide decreases insulin resistance induced by high-fructose feeding. Horm Metab Res 2000; 32: 339-342
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Li P, Koike T, Qin B, Kubota M, Kawata Y, Jia YJ, Oshida Y. A high-fructose diet impairs Akt and PKCzeta phosphorylation and GLUT4 translocation in rat skeletal muscle. Horm Metab Res 2008; 40: 528-532
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Iyer SN, Katovich MJ. Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. Am J Hypertens 1996; 9: 662-668
    CrossrefPubMedGoogle Scholar
  • 19 Hsieh PS, Tai YH, Loh CH, Shih KC, Cheng WT, Chu CH. Functional interaction of AT1 and AT2 receptors in fructose-induced insulin resistance and hypertension in rats. Metabolism 2005; 54: 157-164
    CrossrefPubMedGoogle Scholar
  • 20 Luzio SD, Dunseath G, Owens DR. Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes. Horm Metab Res 2002; 34: 271-214
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Sano H, Kane S, Sano E, Miinea CP, Asara JM, Lane WS, Garner CW, Lienhard GE. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 2003; 278: 14599-14602
    CrossrefPubMedGoogle Scholar
  • 22 Miinea CP, Sano H, Kane S, Sano E, Fukuda M, Peranen J, Lane WS, Lienhard GE. AS160, the Akt substrate regulating GLUT4 translocation, has a functional Rab GTPase-activating protein domain. Biochem J 2005; 391 (Pt 1) 87-93
    CrossrefPubMedGoogle Scholar
  • 23 Yayama K, Okamoto H. Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Int Immunopharmacol 2008; 8: 312-318
    CrossrefPubMedGoogle Scholar
  • 24 Nora EH, Munzenmaier DH, Hansen-Smith FM, Lombard JH, Greene AS. Localization of the ANG II type 2 receptor in the microcirculation of skeletal muscle. Am J Physiol 1998; 275 (4 Pt 2) H1395-H1403
    PubMedGoogle Scholar
  • 25 Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, Inoue M, Itoh S, Takamoto I, Sasako T, Kumagai K, Kawai T, Hashimoto S, Kobayashi T, Sato M, Tokuyama K, Nishimura S, Tsunoda M, Ide T, Murakami K, Yamazaki T, Ezaki O, Kawamura K, Masuda H, Moroi M, Sugi K, Oike Y, Shimokawa H, Yanagihara N, Tsutsui M, Terauchi Y, Tobe K, Nagai R, Kamata K, Inoue K, Kodama T, Ueki K, Kadowaki T. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011; 13: 294-307
    CrossrefPubMedGoogle Scholar
  • 26 Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, Liu Z. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 2009; 52: 752-764
    CrossrefPubMedGoogle Scholar
  • 27 Guo Q, Mori T, Jiang Y, Hu C, Ohsaki Y, Yoneki Y, Nakamichi T, Ogawa S, Sato H, Ito S. Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats. Hypertens Res 2012; 35: 48-54
    CrossrefPubMedGoogle Scholar
  • 28 Falkner B, Kushner H. Treatment with metoprolol succinate, a selective beta adrenergic blocker, lowers blood pressure without altering insulin sensitivity in diabetic patients. J Clin Hypertens (Greenwich) 2008; 10: 51-57
    CrossrefPubMedGoogle Scholar
  • 29 Zhou MS, Schulman IH, Raij L. Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension. Am J Physiol Heart Circ Physiol 2009; 296: H833-H839
    CrossrefPubMedGoogle Scholar
  • 30 Poy MN, Yang Y, Rezaei K, Fernstrom MA, Lee AD, Kido Y, Erickson SK, Najjar SM. CEACAM1 regulates insulin clearance in liver. Nat Genet 2002; 30: 270-276
    CrossrefPubMedGoogle Scholar
  • 31 Qin B, Nagasaki M, Ren M, Bajotto G, Oshida Y, Sato Y. Cinnamon extract prevents the insulin resistance induced by a high-fructose diet. Horm Metab Res 2004; 36: 119-125
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Koshinaka K, Oshida Y, Han YQ, Ohsawa I, Sato Y. The effect of nitric oxide synthase inhibitor on improved insulin action by pioglitazone in high-fructose-fed rats. Metabolism 2004; 53: 22-27
    CrossrefPubMedGoogle Scholar